|
1
|
Haugen BR, Sawka AM, Alexander EK, Bible
KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini
F, et al: American thyroid association guidelines on the management
of thyroid nodules and differentiated thyroid cancer task force
review and recommendation on the proposed renaming of encapsulated
follicular variant papillary thyroid carcinoma without invasion to
noninvasive follicular thyroid neoplasm with papillary-like nuclear
features. Thyroid. 27:481–483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hao Y, Pan C, Chen W, Zhu WZ and Qi JP:
Differentiation between malignant and benign thyroid nodules and
stratification of papillary thyroid cancer with aggressive
histological features: Whole-lesion diffusion-weighted imaging
histogram analysis. J Magn Reson Imaging. 44:1546–1555. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fusco A, Chiappetta G, Hui P, Rostan GG,
Golden L, Kinder BK, Dillon DA, Giuliano A, Cirafici AM, Santoro M,
Rosai J, et al: Assessment of RET/PTC oncogene activation and
clonality in thyroid nodules with incomplete morphological evidence
of papillary carcinoma: A search for the early precursors of
papillary cancer. Am J Pathol. 160:2157–2167. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jolly LA, Novitskiy S, Owens P, Massoll N,
Cheng N, Fang W, Moses HL and Franco AT: Fibroblast-mediated
collagen remodeling within the tumor microenvironment facilitates
progression of thyroid cancers driven by BrafV600E and Pten loss.
Cancer Res. 76:1804–1813. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brace MD, Wang J, Petten M, Bullock MJ,
Makki F, Trites J, Taylor SM and Hart RD: Differential expression
of transforming growth factor-beta in benign vs. papillary thyroid
cancer nodules; a potential diagnostic tool? J Otolaryngol Head
Neck Surg. 43:222014.
|
|
6
|
Hwang S, Shin DY, Kim EK, Yang WI, Byun
JW, Lee SJ, Kim G, Im SJ and Lee EJ: Focal lymphocytic thyroiditis
nodules share the features of papillary thyroid cancer on
ultrasound. Yonsei Med J. 56:1338–1344. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baldini E, Tuccilli C, Prinzi N, Sorrenti
S, Falvo L, Vito CD, Catania A, Tartaglia F, Mocini R, Coccaro C,
et al: Deregulated expression of Aurora kinases is not a prognostic
biomarker in papillary thyroid cancer patients. PLoS One.
10:e01215142015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Komatsu S, Ichikawa D, Takeshita H,
Morimura R, Hirajima S, Tsujiura M, Kawaguchi T, Miyamae M, Nagata
H, Hirotaka K, et al: Circulating miR-18a: A sensitive cancer
screening biomarker in human cancer. In Vivo. 28:293–297.
2014.PubMed/NCBI
|
|
9
|
Kurashige J, Mima K, Sawada G, Takahashi
Y, Eguchi H, Sugimachi K, Mori M, Yanagihara K, Yashiro M, Hirakawa
K, et al: Epigenetic modulation and repression of miR-200b by
cancer-associated fibroblasts contribute to cancer invasion and
peritoneal dissemination in gastric cancer. Carcinogenesis.
36:133–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang XZ, Hang YK, Liu JB, Hou YQ, Wang N
and Wang MJ: Over-expression of microRNA-375 inhibits papillary
thyroid carcinoma cell proliferation and induces cell apoptosis by
targeting ERBB2. J Pharmacol Sci. 130:78–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chou CK, Liu RT and Kang HY:
MicroRNA-146b: A novel biomarker and therapeutic target for human
papillary thyroid cancer. Int J Mol Sci. 18:2017. View Article : Google Scholar
|
|
12
|
Dai L, Wang Y, Chen L, Zheng J, Li J and
Wu X: MiR-221, a potential prognostic biomarker for recurrence in
papillary thyroid cancer. World J Surg Oncol. 15:112017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiong Y, Kotian S, Zeiger MA, Zhang L and
Kebebew E: miR-126-3p inhibits thyroid cancer cell growth and
metastasis, and is associated with aggressive thyroid cancer. PLoS
One. 10:e01304962015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A,
Gundara JS, Ip JC, Glover A, Sywak MS, Delbridge LW, Robinson BG
and Sidhu SB: MicroRNA-222 and microRNA-146b are tissue and
circulating biomarkers of recurrent papillary thyroid cancer.
Cancer. 119:4358–4365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu H, Huang X and Ye T: MiR-22
down-regulates the proto-oncogene ATP citrate lyase to inhibit the
growth and metastasis of breast cancer. Am J Transl Res.
10:659–669. 2018.PubMed/NCBI
|
|
16
|
Chen Z, Shen A, Liu L, Chen Y, Chu J, Cai
Q, Qi F, Sferra TJ and Peng J: Pien Tze Huang induces apoptosis and
inhibits proliferation of 5-fluorouracil-resistant colorectal
carcinoma cells via increasing miR-22 expression. Exp Ther Med.
14:3533–3540. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Domper Arnal MJ and Ferrandez Arenas Á:
and Lanas Arbeloa Á: Esophageal cancer: Risk factors, screening and
endoscopic treatment in Western and Eastern countries. World J
Gastroenterol. 21:7933–7943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benjamin H, Schnitzer-Perlman T, Shtabsky
A, VandenBussche CJ, Ali SZ, Kolar Z and Pagni F;: Rosetta Genomics
Group, Bar D and Meiri E: Analytical validity of a microRNA-based
assay for diagnosing indeterminate thyroid FNA smears from
routinely prepared cytology slides. Cancer Cytopathol. 124:711–721.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qu K, Pan Q, Zhang X, Rodriguez L, Zhang
K, Li H, Ho A, Sanders H, Sferruzza A, Cheng SM, et al: Detection
of BRAF V600 mutations in metastatic melanoma: Comparison of the
Cobas 4800 and Sanger sequencing assays. J Mol Diagn. 15:790–795.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoon JH, Lee HS, Kim EK, Moon HJ and Kwak
JY: Thyroid nodules: Nondiagnostic cytologic results according to
thyroid imaging reporting and data system before and after
application of the bethesda system. Radiology. 276:579–587. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moon HJ, Kim EK, Yoon JH and Kwak JY:
Malignancy risk stratification in thyroid nodules with
nondiagnostic results at cytologic examination: Combination of
thyroid imaging reporting and data system and the Bethesda System.
Radiology. 274:287–295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang J, Liu BJ, Xu HX, Xu JM, Zhang YF,
Liu C, Wu J, Sun LP, Guo LH, Liu LN, et al: Prospective validation
of an ultrasound-based thyroid imaging reporting and data system
(TI-RADS) on 3980 thyroid nodules. Int J Clin Exp Med. 8:5911–5917.
2015.PubMed/NCBI
|
|
24
|
Rodolico V, Cabibi D, Pizzolanti G,
Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A
and Giordano C: BRAF V600E mutation and p27 kip1 expression in
papillary carcinomas of the thyroid <or=1 cm and their paired
lymph node metastases. Cancer. 110:1218–1226. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pesutic-Pisac V, Punda A, Gluncic I and
Bedeković V: Kragić AP and Kunac N: Cyclin D1 and p27 expression as
prognostic factor in papillary carcinoma of thyroid: Association
with clinicopathological parameters. Croat Med J. 49:643–649. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nguyen QT, Lee EJ, Huang MG, Park YI,
Khullar A and Plodkowski RA: Diagnosis and treatment of patients
with thyroid cancer. Am Health Drug Benefits. 8:30–40.
2015.PubMed/NCBI
|
|
27
|
Baldini E, Sorrenti S, Tuccilli C, Prinzi
N, Coccaro C, Catania A, Filippini A, Bononi M, Antoni ED,
D'Armiento M and Ulisse S: Emerging molecular markers for the
prognosis of differentiated thyroid cancer patients. Int J Surg. 12
(Suppl):S52–S56. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cohen Y, Xing M, Mambo E, Guo Z, Wu G,
Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF
mutation in papillary thyroid carcinoma. J Natl Cancer Inst.
95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: Genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
30
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Millington GWM. Mutations of the BRAF gene
in human cancer. Davies, et al: (Nature 2002; 417 949 54). Clin Exp
Dermatol. 38:222–223. 2013.PubMed/NCBI
|
|
32
|
Li QK, Nugent SL, Straseski J, Cooper D,
Riedel S, Askin FB and Sokoll LJ: Thyroglobulin measurements in
fine-needle aspiration cytology of lymph nodes for the detection of
metastatic papillary thyroid carcinoma. Cancer Cytopathol.
121:440–448. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hanna AN, Michael CW and Jing X: Mixed
medullary-follicular carcinoma of the thyroid: Diagnostic dilemmas
in fine-needle aspiration cytology. Diagn Cytopathol. 39:862–865.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Frasoldati A and Valcavi R: Challenges in
neck ultrasonography: Lymphadenopathy and parathyroid glands.
Endocr Pract. 10:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Anadol E, Schierwagen R, Elfimova N, Tack
K, Schwarze-Zander C, Eischeid H, Noetel A, Boesecke C, Jansen C,
Dold L, et al: Circulating microRNAs as a marker for liver injury
in human immunodeficiency virus patients. Hepatology. 61:46–55.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maciejak A, Kiliszek M, Opolski G, Segiet
A, Matlak K, Dobrzycki S, Tulacz D, Sygitowicz G, Burzynska B and
Gora M: miR-22-5p revealed as a potential biomarker involved in the
acute phase of myocardial infarction via profiling of circulating
microRNAs. Mol Med Rep. 14:2867–2875. 2016. View Article : Google Scholar : PubMed/NCBI
|
